Cargando…
Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammat...
Autores principales: | Desilles, J. P., Gregoire, C., Le Cossec, C., Lambert, J., Mophawe, O., Losser, M. R., Lambiotte, F., Le Tacon, S., Cantier, M., Engrand, N., Trouiller, P., Pottecher, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303591/ https://www.ncbi.nlm.nih.gov/pubmed/32560746 http://dx.doi.org/10.1186/s13063-020-04488-8 |
Ejemplares similares
-
Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers
por: Chang, Kyung Hwa, et al.
Publicado: (2020) -
The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023) -
Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients
por: Pottecher, Julien, et al.
Publicado: (2020) -
Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
por: Earhart, A.P., et al.
Publicado: (2020) -
The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
por: Toma, Andrew, et al.
Publicado: (2021)